(5E)-5-[(1H-Indol-3-yl)methylidene]-3-(prop-2-en-1-yl)-2-sulfanylidene-1,3-thiazolidin-4-one

Catalog No. :
ACNFIS873
CAS No. :
92437-37-1
Molecular Formula :
C15H12N2OS2
Molecular Weight :
300.41

IUPAC Name:(E)-5-((1H-indol-3-yl)methylene)-3-allyl-2-thioxothiazolidin-4-one

(5E)-5-[(1H-Indol-3-yl)methylidene]-3-(prop-2-en-1-yl)-2-sulfanylidene-1,3-thiazolidin-4-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$315.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(5E)-5-[(1H-Indol-3-yl)methylidene]-3-(prop-2-en-1-yl)-2-sulfanylidene-1,3-thiazolidin-4-one
IUPAC Name(E)-5-((1H-indol-3-yl)methylene)-3-allyl-2-thioxothiazolidin-4-one
MDL No.MFCD00642874
Molecular FormulaC15H12N2OS2
Molecular Weight300.41
SMILESC=CCN1C(=O)/C(=C\C2=CNC3=C2C=CC=C3)SC1=S
InChI KeyHXSMOJUQQNQUTI-MDWZMJQESA-N
Synonym3-allyl-5-(1H-indol-3-ylmethylene)-2-thioxo-1,3-thiazolidin-4-one;4-Thiazolidinone, 5-(1H-indol-3-ylmethylene)-3-(2-propen-1-yl)-2-thioxo-
CAS No.92437-37-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACNFIS873 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACOHWJ835 route compound structure diagram
    ACOHWJ835487-89-8 In Stock
  4. Then
  5. ACNFIS873 route product structure diagram
    ACNFIS87392437-37-1
Inquiry

2. ACNFIS873 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNFIS873 route product structure diagram
    ACNFIS87392437-37-1
Inquiry

Comments (0)